Research increasingly supports semaglutide (the active ingredient in Ozempic) as an effective treatment for women with PCOS, particularly for reducing weight, improving insulin resistance, and restoring hormonal balance. While Ozempic doesn’t carry an FDA indication for PCOS, clinical studies and real-world prescribing data show that GLP-1 receptor agonists address several of the core metabolic drivers behind polycystic ovary syndrome. Here’s a closer look at what the science actually says.<\/p>\n
PCOS isn’t just a reproductive disorder. At its core, it’s a metabolic condition with reproductive consequences. Understanding this distinction matters because it explains why a diabetes and weight loss medication like semaglutide can have such a broad impact on PCOS symptoms.<\/p>\n
The metabolic dysfunction in PCOS typically starts with insulin resistance. When cells stop responding normally to insulin, the pancreas pumps out more to compensate. That excess insulin does two damaging things simultaneously. It promotes fat storage, especially visceral fat around the abdomen, and it signals the ovaries to overproduce androgens like testosterone.<\/p>\n
Elevated androgens then cause many of the symptoms women associate with PCOS: irregular or absent periods, acne, excess facial and body hair, and hair thinning on the scalp. The excess weight that insulin resistance encourages further worsens inflammation and hormone imbalance, creating a feedback loop that’s incredibly difficult to break through lifestyle changes alone.<\/p>\n
This is the cycle that semaglutide can interrupt.<\/p>\n